Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“ASCO 2026 Abstracts Released! Over the next few weeks, I’ll preview a few noteworthy presentations for the breast oncology community.
OPTIMA (Phase 3 | May 30, 2026)
In premenopausal, node+ HR+ disease:
Is chemo benefit solely cytotoxic…or just ovarian suppression or both?
Key inclusion:
- Age ≥40
- Luminal breast cancer
- pN1–2, or pN1mi + pT ≥2 cm, or pN0 + pT ≥3 cm
Design:
- Prosigna-guided
- Low score (<60) – ET + mandated OFS
- High score (>60) – chemo + ET
- Adjuvant abemaciclib ALLOWED
Why it matters:
Builds on RxPONDER trial + TAILORx trial
Tests endocrine optimization vs chemo in pts ≥40
If positive – chemo may be avoidable in a subset we routinely treat and struggle to discuss true impact of chemotherapy for. One trial we’ve been waiting for some time!”
Other articles featuring Matthew Kurian on OncoDaily.